Background and objectives: We sought to identify early factors associated with relapse and outcome in paediatric-onset myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD). Methods: In a multicenter retrospective cohort of pediatric MOGAD (≤18 years), onset features and treatment were compared in patients with monophasic vs relapsing disease (including cases with follow-up ≥12 months after onset or relapse at any time) and in patients with final Expanded Disability Status Scale (EDSS) 0 vs ≥1 at last follow-up (including cases with follow-up >3 months after last event or EDSS0 at any time). Multivariable logistic regression models were used to evaluate factors associated with relapsing disease course and EDSS ≥ 1 at final follow-up. Results: Seventy-five children were included (median onset age 7 years; median 30 months of follow-up). Presentation with acute disseminated encephalomyelitis was more frequent in children aged 8 years or younger (66.7%, 28/42) than in older patients (30.3%, 10/33) (p = 0.002), whereas presentation with optic neuritis was more common in children older than 8 years (57.6%, 19/33) than in younger patients (21.4%, 9/42) (p = 0.001). 40.0% (26/65) of patients relapsed. Time to first relapse was longer in children aged 8 years or younger than in older patients (median 18 vs 4 months) (p = 0.013). Factors at first event independently associated with lower risk of relapsing disease course were immunotherapy <7 days from onset (6.7-fold reduced odds of relapsing course, OR 0.15, 95% CI 0.03-0.61, p = 0.009), corticosteroid treatment for ≥5 weeks (6.7-fold reduced odds of relapse, OR 0.15, 95% CI 0.03-0.80, p = 0.026), and abnormal optic nerves on onset MRI (12.5-fold reduced odds of relapse, OR 0.08, 95% CI 0.01-0.50, p = 0.007). 21.1% (15/71) had EDSS ≥ 1 at final follow-up. Patients with a relapsing course had a higher proportion of final EDSS ≥ 1 (37.5%, 9/24) than children with monophasic disease (12.8%, 5/39) (p = 0.022, univariate analysis). Each 1-point increment in worst EDSS at onset was independently associated with 6.7-fold increased odds of final EDSS ≥ 1 (OR 6.65, 95% CI 1.33-33.26, p = 0.021). Discussion: At first attack of pediatric MOGAD, early immunotherapy, longer duration of corticosteroid treatment, and abnormal optic nerves on MRI seem associated with lower risk of relapse, whereas higher disease severity is associated with greater risk of final disability (EDSS ≥ 1).

Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD / Nosadini, Margherita; Eyre, Michael; Giacomini, Thea; Valeriani, Massimiliano; Della Corte, Marida; Praticò, Andrea D; Annovazzi, Pietro; Cordani, Ramona; Cordelli, Duccio Maria; Crichiutti, Giovanni; Di Rosa, Gabriella; Dolcemascolo, Valentina; Fetta, Anna; Freri, Elena; Gallo, Paolo; Gastaldi, Matteo; Granata, Tiziana; Grazian, Luisa; Iorio, Raffaele; Lombardini, Martina; Margoni, Monica; Mariotto, Sara; Matricardi, Sara; Melani, Federico; Nardocci, Nardo; Papetti, Laura; Passarini, Alice; Pisani, Francesco; Po', Chiara; Puthenparampil, Marco; Ragona, Francesca; Savasta, Salvatore; Siliquini, Sabrina; Toldo, Irene; Tozzo, Alessandra; Turco, Emanuela Claudia; Varone, Antonio; Vogrig, Alberto; Zuliani, Luigi; Bugin, Samuela; Rossato, Sara; Orsini, Alessandro; Cantalupo, Gaetano; Mancardi, Maria Margherita; Ferilli, Michela Ada Noris; Foiadelli, Thomas; Sartori, Stefano. - In: NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION. - ISSN 2332-7812. - 10:1(2023), p. e200065. [10.1212/NXI.0000000000200065]

Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD

Pisani, Francesco;
2023

Abstract

Background and objectives: We sought to identify early factors associated with relapse and outcome in paediatric-onset myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD). Methods: In a multicenter retrospective cohort of pediatric MOGAD (≤18 years), onset features and treatment were compared in patients with monophasic vs relapsing disease (including cases with follow-up ≥12 months after onset or relapse at any time) and in patients with final Expanded Disability Status Scale (EDSS) 0 vs ≥1 at last follow-up (including cases with follow-up >3 months after last event or EDSS0 at any time). Multivariable logistic regression models were used to evaluate factors associated with relapsing disease course and EDSS ≥ 1 at final follow-up. Results: Seventy-five children were included (median onset age 7 years; median 30 months of follow-up). Presentation with acute disseminated encephalomyelitis was more frequent in children aged 8 years or younger (66.7%, 28/42) than in older patients (30.3%, 10/33) (p = 0.002), whereas presentation with optic neuritis was more common in children older than 8 years (57.6%, 19/33) than in younger patients (21.4%, 9/42) (p = 0.001). 40.0% (26/65) of patients relapsed. Time to first relapse was longer in children aged 8 years or younger than in older patients (median 18 vs 4 months) (p = 0.013). Factors at first event independently associated with lower risk of relapsing disease course were immunotherapy <7 days from onset (6.7-fold reduced odds of relapsing course, OR 0.15, 95% CI 0.03-0.61, p = 0.009), corticosteroid treatment for ≥5 weeks (6.7-fold reduced odds of relapse, OR 0.15, 95% CI 0.03-0.80, p = 0.026), and abnormal optic nerves on onset MRI (12.5-fold reduced odds of relapse, OR 0.08, 95% CI 0.01-0.50, p = 0.007). 21.1% (15/71) had EDSS ≥ 1 at final follow-up. Patients with a relapsing course had a higher proportion of final EDSS ≥ 1 (37.5%, 9/24) than children with monophasic disease (12.8%, 5/39) (p = 0.022, univariate analysis). Each 1-point increment in worst EDSS at onset was independently associated with 6.7-fold increased odds of final EDSS ≥ 1 (OR 6.65, 95% CI 1.33-33.26, p = 0.021). Discussion: At first attack of pediatric MOGAD, early immunotherapy, longer duration of corticosteroid treatment, and abnormal optic nerves on MRI seem associated with lower risk of relapse, whereas higher disease severity is associated with greater risk of final disability (EDSS ≥ 1).
2023
Adrenal Cortex Hormones, Disease progression, Immunotherapy
01 Pubblicazione su rivista::01a Articolo in rivista
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD / Nosadini, Margherita; Eyre, Michael; Giacomini, Thea; Valeriani, Massimiliano; Della Corte, Marida; Praticò, Andrea D; Annovazzi, Pietro; Cordani, Ramona; Cordelli, Duccio Maria; Crichiutti, Giovanni; Di Rosa, Gabriella; Dolcemascolo, Valentina; Fetta, Anna; Freri, Elena; Gallo, Paolo; Gastaldi, Matteo; Granata, Tiziana; Grazian, Luisa; Iorio, Raffaele; Lombardini, Martina; Margoni, Monica; Mariotto, Sara; Matricardi, Sara; Melani, Federico; Nardocci, Nardo; Papetti, Laura; Passarini, Alice; Pisani, Francesco; Po', Chiara; Puthenparampil, Marco; Ragona, Francesca; Savasta, Salvatore; Siliquini, Sabrina; Toldo, Irene; Tozzo, Alessandra; Turco, Emanuela Claudia; Varone, Antonio; Vogrig, Alberto; Zuliani, Luigi; Bugin, Samuela; Rossato, Sara; Orsini, Alessandro; Cantalupo, Gaetano; Mancardi, Maria Margherita; Ferilli, Michela Ada Noris; Foiadelli, Thomas; Sartori, Stefano. - In: NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION. - ISSN 2332-7812. - 10:1(2023), p. e200065. [10.1212/NXI.0000000000200065]
File allegati a questo prodotto
File Dimensione Formato  
Early Immunotherapy.pdf

accesso aperto

Note: Nosadini_Early Immunotherapy_2023
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 505.1 kB
Formato Adobe PDF
505.1 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1665613
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 10
social impact